Protein Summary
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells (PubMed:16286016). Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an "alarmin", that amplifies immune responses during tissue injury (PubMed:17853410, PubMed:18836528). In quiescent endothelia the uncleaved form is constitutively and abundantly expressed, and acts as a chromatin-associated nuclear factor with transcriptional repressor properties, it may sequester nuclear NF-kappaB/RELA, lowering expression of its targets (PubMed:21734074). This form is rapidely lost upon angiogenic or proinflammatory activation (PubMed:18787100). The protein encoded by this gene is a cytokine that binds to the IL1RL1/ST2 receptor. The encoded protein is ...more
- ENST00000381434
- ENSP00000370842
- ENSG00000137033
- ENST00000417746
- ENSP00000394039
- ENST00000456383
- ENSP00000414238
- ENST00000611532
- ENSP00000478858
- C9orf26
- IL1F11
- NFHEV
- DVS27
- IL1F11
- NF-HEV
- NFEHEV
- C9orf26
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
biological process | 0.98 | ||
biological term | 0.98 | ||
gene perturbation | 0.98 | ||
disease | 0.66 | ||
phenotype | 0.62 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2231.36 (req: < 5)
Gene RIFs: 684 (req: <= 3)
Antibodies: 993 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2231.36 (req: >= 5)
Gene RIFs: 684 (req: > 3)
Antibodies: 993 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 23
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0